minocycline foam rosacea Zilxi
Selected indexed studies
- Minocycline foam (Zilxi) for rosacea. (Med Lett Drugs Ther, 2020) [PMID:33429414]
- Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials. (J Am Acad Dermatol, 2020) [PMID:32004648]
- Emerging Medical Therapies in Rosacea: A Narrative Review. (Dermatol Ther (Heidelb), 2023) [PMID:37824060]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Minocycline foam (Zilxi) for rosacea. (2020) pubmed
- Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials. (2020) pubmed
- Efficacy and safety of topical minocycline preparations for papulopustular rosacea: a systematic review and meta-analysis. (2025) pubmed
- Safety and Pharmacokinetics of FMX103 (1.5% Minocycline Topical Foam) in Subjects with Moderate-to-Severe Papulopustular Rosacea under Maximum-use Treatment Conditions. (2021) pubmed
- Emerging Medical Therapies in Rosacea: A Narrative Review. (2023) pubmed
- Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX103 1.5% Minocycline Topical Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea. (2020) pubmed
- A Phase II, Randomized, Double-Blind Clinical Study Evaluating the Safety, Tolerability, and Efficacy of a Topical Minocycline Foam, FMX103, for the Treatment of Facial Papulopustular Rosacea. (2018) pubmed
- Microencapsulated Benzoyl Peroxide for Rosacea in Context: A Review of the Current Treatment Landscape. (2024) pubmed
- Black veins: a case of minocycline-induced pigmentation post-sclerotherapy and a review of literature. (2017) pubmed
- A Review of the Diagnostic and Therapeutic Gaps in Rosacea Management: Consensus Opinion. (2024) pubmed